Head-To-Head Contrast: Northwest Biotherapeutics (OTCMKTS:NWBO) versus Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) and Northwest Biotherapeutics (OTCMKTS:NWBO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Northwest Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34 billion	5.79	$4.50 billion	$40.46	19.92
Northwest Biotherapeutics	$1.38 million	226.42	-$60.16 million	($18.23)	-0.01

Regeneron Pharmaceuticals has higher revenue and earnings than Northwest Biotherapeutics. Northwest Biotherapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Regeneron Pharmaceuticals and Northwest Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0	10	16	0	2.62
Northwest Biotherapeutics	0	0	0	0	0.00

Regeneron Pharmaceuticals currently has a consensus target price of $793.74, indicating a potential downside of 1.52%. Given Regeneron Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Northwest Biotherapeutics.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Northwest Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Northwest Biotherapeutics	-2,931.73%	N/A	-79.26%

Institutional & Insider Ownership

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Northwest Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Northwest Biotherapeutics on 13 of the 14 factors compared between the two stocks.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.